10X Genomics

Pleasanton, United States Founded: 2012 • Age: 14 yrs Listed
Instrument systems for genomic research and sequencing libraries are developed.

About 10X Genomics

10X Genomics is a publicly listed company based in Pleasanton (United States) founded in 2012. Instrument systems for genomic research and sequencing libraries are developed. 10X Genomics has raised $199.9 million across 7 funding rounds from investors including Fidelity Investments, SVB and SoftBank Group. The company has 1,310 employees. 10X Genomics has completed 7 acquisitions, including CARTANA, Epinomics and Proteintech Group. Its website 10xgenomics.com draws about 251 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its competitors include Mission Bio, Element Biosciences and Cellares; 3 of its 3 listed competitors have raised funding.

Company details

10X Genomics was founded in 2012 and is headquartered in Pleasanton, United States. Instrument systems for genomic research are developed, including the Chromium platform with reagents and consumables for preparing sequencing libraries compatible with Illumina systems. Software for sequence analysis is provided, along with services such as whole-genome sequencing and exome sequencing. Operations focus on partitioning cells or DNA fragments via GemCode technology to enable barcoded libraries.

Key Metrics
  • Annual Revenue
    $642.82 M (USD)
    5.25
    as on Dec 31, 2025
  • Net Profit
    -$43.54 M (USD)
    76.16
    as on Dec 31, 2025
  • EBITDA
    -$56.38 M (USD)
    62.03
    as on Dec 31, 2025
  • Total Equity Funding
    $199.9M (USD)

    in 7 rounds

  • Latest Funding Round
    $85M (USD), Series D

    Jan 2019

  • Investors
  • Employee Count
    1,310
  • Investments & Acquisitions
    CARTANA

    & 6 more

Apps and channels of 10X Genomics

its YouTube channel 10x Genomics has 6.98K subscribers and 30 videos.

10x Genomics
YouTube 6.98K subscribers 30 videos Science & Technology
Open channel

Videos from 10X Genomics

The most watched videos on 10X Genomics's YouTube channel, 10x Genomics (6.98K subscribers). Click a video to play it here.

Explore Visium HD Data in less than 13 Minutes – Loupe Browser Tutorial
3K views
Life at 10x Genomics
1.5K views
【空間的解析】東京大学の鈴木穣先生、鈴木絢子先生に聞くXeniumが可能にする空間的解析の世界
1K views
Experience the power of spatial transcriptomics from 10x Genomics Part 2
689 views

More on 10x Genomics.

Funding Insights of 10X Genomics

10X Genomics has successfully raised a total of $199.9M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $85 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $199.9M
  • Total Rounds 7
  • Last Round Series D — $85M
  • First Round $3M

    (Nov 2012)

  • Investors Count 10

All 7 funding rounds of 10X Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2019$85MSeries D–Meritech, Wells Fargo
Jan 2019$161,163Grant––
Apr 2018$75MDebt – Venture––
Mar 2016$55MSeries C–Fidelity Investments
Mar 2015$55.5MSeries B––
May 2013$1.4MSeries A––
–
Nov 2012$3MSeries A––
–
Valuation history

10 investors in total: 10 institutional.

Investors in 10X Genomics

10X Genomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, SVB and SoftBank Group.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity investments are directed toward US-based companies.
meritechcapital.comPalo Alto, United States
Venture capital is invested in multiple sectors by Paladin Capital.
paladincapgroup.comWashington, Dc, United States
Multi-stage investment firm invests in healthcare and life sciences companies
foresitecapital.comNew York, United States
Venture capital firm focused on tech sectors
venrock.comPalo Alto, United States
Venture capital investments in technology and startups.
2016visionfund.comLondon, United Kingdom
Diverse financial services and online banking are provided to clients.
1852wellsfargo.comSan Francisco, United States
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
1946fidelity.comBoston, United States
Investments are directed toward multiple sectors via fund of funds.
1981group.softbankMinato City, Japan
Banking services are provided to innovative companies, investors, and individuals.
1983svb.comSanta Clara, United States
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for 10X Genomics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of 10X Genomics

339 people are tracked at 10X Genomics (80 in leadership, 6 in board & advisors, 253 in team); the tracked headcount is 1,310.

NameRoleGroup
Shawn Phillips
Leadership
Adam Taich
Chief Financial OfficerLeadership
Estevan Avila
Vice President Business Solutions And ProgramsLeadership
Rich Ruiz
Senior Director, Global Supply ChainLeadership
Di Mo
Vice President Of Sales - APACLeadership
Angelique H.
Sr. Director, Corporate Marketing & AMER Regional MarketingLeadership
Ben Hindson
Chief Scientific Officer, President & Co-FounderLeadership
Anne Readel
Director, Transactions CounselLeadership
Richard Gardner
VP Corporate ControllerLeadership
Anita Vanhall
Vp, Tax & TreasuryLeadership
Mennah Moustafa
Chief Commercial Officer (cco)Leadership
Randy Wu
Vice President Of Intellectual Property And LitigationLeadership
Rajiv Bharadwaj
Vice President, R&dLeadership
Richard Lee
Director Of SalesLeadership
Deepthi Vijayraghavan
Commercial Chief Of StaffLeadership
Robert Walters
Sales Director Europe, Latin America, Middle East And Africa At 10x GenomicsLeadership
Jaclyn Z. Damico
Director Of Sales, EastLeadership
Venkataraghavan Gandur
Sr Director Of Data PlatformLeadership
Michael Schnall-Levin
Chief Technology Officer, Founding ScientistLeadership
Brian Olson
Director, ManufacturingLeadership

319 more people are available in the full profile.

Premium access

Complete people profiles for 10X Genomics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of 10X Genomics

10X Genomics is a publicly listed company on the NASDAQ with ticker symbol TXG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date12 Sep 2019
  • Listed onNASDAQ: TXG
  • Listed entity10x Genomics, Inc.
  • Exchange sectorHealth technology
  • ISINUS88025U1097
  • Share price$71.79 (-4.52% on the day) · 2026-10-13
  • Market capitalisation$9.35B
  • EPS (diluted, trailing year)$-0.59
  • Volume (last session)4,041,152

Financials of 10X Genomics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$642.8M-$43.5M-$56.4M
2024$610.8M-$182.6M-$148.5M
2023$618.7M-$255.1M-$158.2M
2022$516.4M-$166.0M-$130.7M
2021$490.5M-$58.2M-$24.7M
Premium access

Detailed financial statements for 10X Genomics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by 10X Genomics

10X Genomics has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include CARTANA, Epinomics and Proteintech Group.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Supplies high-quality antibodies, immunoassays, and cytokines for scientific applications globally.
ptglab.comChicago, United States2002Jun 2026••••
Scale Biosciences is a company developing single-cell library preparation kits for genomic, epigenomic, and transcriptomic analysis.
scale.bioSan Diego, United States2020Aug 2025••••
Antigens, peptides, and tetramers for research are supplied online.
tetramer-shop.comKongens Lyngby, Denmark2018Feb 2021••••
Fluorescent in situ RNA sequencing technology
readcoor.comCambridge, United States2016Oct 2020$350M
Provider of gene expression mapping technology in brain tissue
cartana.seSolna, Sweden2017Aug 2020$41.2M
Tools for gene expression visualization in tissue samples are provided.
spatialtranscriptomics.comSolna, Sweden2013Dec 2018••••
Epigenomics research and development services for DNA sequencing are provided.
epinomics.coSan Francisco, United States2013Aug 2018••••
Premium access

Complete acquisition details for 10X Genomics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of 10X Genomics

11 dated milestones of 10X Genomics across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded 10X Genomics is founded.
  2. Funding First funding round of $3.0M.
  3. Acquisition Acquires Epinomics.
  4. Acquisition Acquires Spatial Transcriptomics.
  5. Funding Latest funding round, Series D, of $85.0M.
  6. IPO Lists on the stock exchange (IPO).
  7. Acquisition Acquires CARTANA.
  8. Acquisition Acquires ReadCoor.
  9. Acquisition Acquires Tetramer Store.
  10. Acquisition Acquires Scale Biosciences.
  11. Acquisition Acquires Proteintech Group.

Competitors of 10X Genomics

10X Genomics has 3 listed competitors in our database, 3 of them funded. They include Mission Bio, Element Biosciences and Cellares.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
missionbio.com2014San Francisco, United States$110M109
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
elementbiosciences.com2017San Diego, United States$678.3M
Benchtop DNA sequencers are developed for research and diagnostic uses.
cellares.com2019San Francisco, United States$355M
Medical devices for cell-based therapy manufacturing are produced.
Premium access

Detailed competitors of 10X Genomics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of 10X Genomics

The website of 10X Genomics (10xgenomics.com) receives about 251.3K visits a month.

  • Monthly visits
    251.3K

    ▲ 22.4% vs previous month

Similar websites

Websites whose visitors overlap most with 10X Genomics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
biorxiv.org
100%
3M#19,954View details
satijalab.org
satijalab.org
98%
#345,259–
cell.com
97%
5M#14,619View details
biostars.org
95%
#154,376View details
bioconductor.org
93%
#143,754View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for 10X Genomics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as 10X Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about 10X Genomics

Premium access

Complete news archive for 10X Genomics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about 10X Genomics

10X Genomics was founded in 2012.

10X Genomics is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.

10X Genomics is a funded company, having raised a total of $199.9M across 7 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Nov 2012.

10X Genomics has 1,310 employees.

Annual revenue of 10X Genomics is $642.82M as on Dec 31, 2025.

10X Genomics was founded in 2012 and is headquartered in Pleasanton, United States. Instrument systems for genomic research are developed, including the Chromium platform with reagents and consumables for preparing sequencing libraries compatible with Illumina systems. Software for sequence analysis is provided, along with services such as whole-genome sequencing and exome sequencing. Operations focus on partitioning cells or DNA fragments via GemCode technology to enable barcoded libraries.

10X Genomics's top competitors include Mission Bio, Element Biosciences and Cellares.

Yes, 10X Genomics is publicly traded on NASDAQ under the ticker symbol TXG.

10X Genomics has made 7 acquisitions, including CARTANA, Epinomics, and Proteintech Group.

10X Genomics has 10 investors. Key investors include Fidelity Investments, SVB, SoftBank Group, Wells Fargo, and European Union.

The website of 10X Genomics receives about 251 thousand visits a month.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available